Live SpaceX Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Replimune Group, Inc.

Get SEC filing alerts via email and in your feed for Replimune Group, Inc.

REPL

Replimune Group, Inc.

About Replimune Group, Inc.

Replimune Group, Inc. is a biotechnology company specializing in oncolytic immunotherapy for cancer treatment. Its proprietary RPx platform uses engineered herpes simplex virus to activate immune responses against tumors, aiming to improve efficacy and safety. The company develops virus-based therapies, including RP1, RP2, and RP3, targeting skin cancers, melanoma, and other tumor types, often in combination with immune checkpoint inhibitors, to enhance anti-tumor immunity.
This description was generated via AI from an annual report. Updated 9 months ago.

Latest SEC Filings from Replimune Group, Inc.

1
1
Replimune Group, Inc. Replimune Group Reports $70.9 Million Net Loss for Quarter Ended December 31, 2025

Via official filing (AI summary) | 4 months ago | 0 comments

2
1
Replimune Group, Inc. Replimune Group Reports $83.1 Million Net Loss in Q2 Fiscal 2025

Via official filing (AI summary) | 7 months ago | 0 comments

3
1
Replimune Group, Inc. Replimune Reports $86.7 Million Net Loss and Increased Operating Expenses for Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

4
1
Replimune Group, Inc. Replimune Reports $247.3 Million Net Loss for Fiscal Year Ending March 31, 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

5
1
Replimune Group, Inc. Replimune Group Reports $66.3 Million Net Loss for Q4 2024, Increases R&D Spending

Via official filing (AI summary) | over 1 year ago | 0 comments

6
1
Replimune Group, Inc. Replimune Group Reports Net Loss of $53.1 Million for Q2 2024, Improves Loss Per Share

Via official filing (AI summary) | over 1 year ago | 0 comments